A Tale of 2s: Optimizing Maternal—Child Health in the Context of Antenatal Maternal Depression and Antidepressant Use

Pedersen LH Henriksen TB Vestergaard M , Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ. 2009;339:b3569.

Alwan S Reefhuis J Rasmussen SA , Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–2692.

Louik C Lin AE Werler MM , First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–2683.

Greene MF . Teratogenicity of SSRIs—serious concern or much ado about little? N Engl J Med. 2007;356(26):2732–2733.

Croen LA Grether JK Yoshida CK , Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–1112.

Zeskind PS Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113(2):368–375.

Nulman I Rovet J Stewart DE , Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336(4):258–262.

Einarson A Schachtschneider AK Halil R , SSRI'S and other antidepressant use during pregnancy and potential neonatal adverse effects: Impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth. 2005;5:11.

Jetter A. Pregnant pause. Vogue (North American Ed). 2009 May. p 144–232. A 3-page article.

Yonkers KA . Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy. Am J Psychiatry. 2009;166(3):268–270.

O'Connor TG Heron J Golding J , Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. Br J Psychiatry. 2002;180:502–508.

Wisner KL . SSRI treatment during pregnancy: Are we asking the right questions? Depress Anxiety. 2010;27(8):695–698.

Lyerly AD Little MO Faden R. The second wave: Toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth. 2008; 1(2): 5–22.

Shea AK Oberlander TF Rurak D. Fetal serotonin reuptake inhibitor antidepressant exposure: Maternal and fetal factors. Can J Psychiatry. 2012;57(9):523–529.

Goodman SH Dimidjian S. The developmental psychopathology of perinatal depression: Implications for psychosocial treatment development and delivery in pregnancy. Can J Psychiatry. 2012;57(9):530–536.

Talge NM Neal C Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: How and why? J Child Psychol Psychiatry. 2007;48(3–4):245–261.

Oberlander TF Warburton W Misri S , Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898–906.

Gaynes BN Gavin N Meltzer-Brody S , Perinatal depression: Prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;(119):1–8.

Altshuler LL Hendrick V Cohen LS . An update on mood and anxiety disorders during pregnancy and the postpartum period. Prim Care Companion J Clin Psychiatry. 2000;2(6):217–222.

Bonari L Pinto N Ahn E , Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726–735.

Grote V Vik T von Kries R , Maternal postnatal depression and child growth: A European cohort study. BMC Pediatr. 2010;10:14.

Oberlander TF Gingrich JA Ansorge MS . Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: Molecular to clinical evidence. Clin Pharmacol Ther. 2009;86(6):672–677.

Kim J Riggs KW Misri S , Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61(2):155–163.

Grote NK Bridge JA Gavin AR , A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10): 1012–1024.

Teixeira JM Fisk NM Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: Cohort based study. BMJ. 1999;318(7177):153–157.

Glover V O'Connor TG . Effects of antenatal stress and anxiety: Implications for development and psychiatry. Br J Psychiatry. 2002;180:389–391.

Orr ST James SA Blackmore PC . Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol. 2002;156(9):797–802.

Gentile S. SSRIs in pregnancy and lactation: Emphasis on neurodevelopmental outcome. CNS Drugs. 2005;19(7):623–633.

Rush AJ Trivedi MH Wisniewski SR , Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163(11): 1905–1917.

Suri R Altshuler L Hellemann G , Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 2007;164(8): 1206–1213.

Wisner KL Sit DK Hanusa BH , Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557–566.

Freeman MP Nolan PE Jr Davis MF , Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28(6):646–653.

Ansorge MS Hen R Gingrich JA . Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol. 2007;7(1):8–17.

Moses-Kolko EL Bogen D Perel J , Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA. 2005;293(19):2372–2383.

Misri S Reebye P Kendrick K , Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry. 2006; 163(6): 1026–1032.

Hilli J Heikkinen T Rontu R , MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol. 2009;19(5):363–370.

Oberlander TF Bonaguro RJ Misri S , Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry. 2008;13(1):65–73.

Fried PA . Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry. 2002;43(1):81–102.

Oberlander TF Reebye P Misri S , Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med. 2007;161:22–29.

Eisenberg L. Nature, niche, and nurture. Acad Psychiatry. 1998;22(4):213–222.

Wisner KL Zarin DA Holmboe ES , Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157(12):1933–1940.

Wisner KL Scholle SH Stein B. Perinatal disorders: Advancing public health opportunities. J Clin Psychiatry. 2008;69(10): 1602–1605.